|
|
|
| Research progress on pathogenesis and molecular targeted therapy of radiation-induced lung injury |
| CHEN Jiazhen, WANG Yu, WANG Cunliang, HU Xudong |
| Department of Radiation Oncology, Shandong Cancer Hospital and Insitute, Shandong First Medical University and Shandong Academy of Medical Scinences, Ji'nan 250117 China |
|
|
|
|
Abstract Radiation-induced lung injury is a common complication of radiotherapy for thoracic tumor, usually involves the radiation-induced pneumonitis at early stage and radiation-induced pulmonary fibrosis at late stage, which seriously affects the treatment and prognosis of patients. At present the common treatments for radiation-induced pulmonary fibrosis include anti-inflammatory therapy, glucocorticoid therapy, antioxidant therapy and so on. Recentlywith the further research of radiation-induced pulmonary fibrosis, more and more attention has attracted in molecular targeted therapy. Molecular targeted inhibitors is a new class of drugs for the treatment of radiation-induced lung injury, mainly targeting a variety of cytokines, signaling pathways, tyrosine kinase receptors and other targets. This article systematically reviews the pathogenesis and molecular targeted therapy of radiation-induced lung injury.
|
|
Received: 22 December 2020
|
|
|
|
|
|
[1] Chen XR, Dong JN, Zhang F, et al. Efficacy and safety of image-guidance radiotherapy by helical tomotherapy in patients with lung cancer[J]. Medicine (Baltimore), 2018, 97(1): e9243. DOI: 10.1097/MD.0000000000009243
[2] Li CC, Chen CY, Chien CR. Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: a population-based propensity-score-matched analysis[J]. Medicine (Baltimore), 2018, 97(22): e10928. DOI: 10.1097/MD.0000000000010928
[3] Ahmed KA, Grass GD, Orman AG, et al. Personalizing radiation treatment delivery in the management of breast cancer[J]. Int J Breast Cancer, 2018, 2018: 6729802. DOI: 10.1155/2018/6729802
[4] Nolan MT, Russell DJ, Negishi K, et al. Meta-analysis of association between mediastinal radiotherapy and long-term heart failure[J]. Am J Cardiol, 2016, 118(11): 1685-1691. DOI: 10.1016/j.amjcard.2016.08.050
[5] Lierova A, Jelicova M, Nemcova M, et al. Cytokines and radiation-induced pulmonary injuries[J]. J Radiat Res, 2018, 59(6): 709-753. DOI: 10.1093/jrr/rry067
[6] Yao Y, Zheng ZL, Song QB. Mesenchymal stem cells: a double-edged sword in radiation-induced lung injury[J]. Thorac Cancer, 2018, 9(2): 208-217. DOI: 10.1111/1759-7714.12573
[7] Giuranno L, Ient J, De Ruysscher D, et al. Radiation-induced lung injury (RILI)[J]. Front Oncol, 2019, 9: 877. DOI: 10.3389/fonc.2019.00877
[8] Beach TA, Groves AM, Johnston CJ, et al. Recurrent DNA damage is associated with persistent injury in progressive radiation-induced pulmonary fibrosis[J]. Int J Radiat Biol, 2018, 94(12): 1104-1115. DOI: 10.1080/09553002.2018.1516907
[9] Almeida C, Nagarajan D, Tian J, et al. The role of alveolar epithelium in radiation-induced lung injury[J]. PLoS One, 2013, 8(1): e53628. DOI: 10.1371/journal.pone.0053628
[10] Hong ZY, Song KH, Yoon JH, et al. An experimental model-based exploration of cytokines in ablative radiation-induced lung injury in vivo and in vitro[J]. Lung, 2015, 193(3): 409-419. DOI: 10.1007/s00408-015-9705-y
[11] Hanania AN, Mainwaring W, Ghebre YT, et al. Radiation-induced lung injury: assessment and management[J]. Chest, 2019, 156(1): 150-162. DOI: 10.1016/j.chest.2019.03.033
[12] 闵茜, 胡伟国, 宋启斌. 放射性肺损伤发生机制的研究进展[J]. 肿瘤学杂志,2016,22(2):88-92. DOI: 10.3969/j.issn.1672-4992.2009.03.075
Min Q, Hu WG, Song QB. Mechanisms of radiation-induced lung injure[J]. J Chin Oncol, 2016, 22(2): 88-92. DOI: 10.3969/j.issn.1672-4992.2009.03.075
[13] Denney L, Byrne AJ, Shea TJ, et al. Pulmonary epithelial cell-derived cytokine TGF-β1 is a critical cofactor for enhanced innate lymphoid cell function[J]. Immunity, 2015, 43(5): 945-958. DOI: 10.1016/j.immuni.2015.10.012
[14] Macias MJ, Martin-Malpartida P, Massagué J. Structural determinants of Smad function in TGF-β signaling[J]. Trends Biochem Sci, 2015, 40(6): 296-308. DOI: 10.1016/j.tibs.2015.03.012
[15] Huang YJ, Zhang WQ, Yu FR, et al. The cellular and molecular mechanism of radiation-induced lung injury[J]. Med Sci Monit, 2017, 23: 3446-3450. DOI: 10.12659/msm.902353
[16] Fan H, Ma LK, Fan B, et al. Role of PDGFR-β/PI3K/AKT signaling pathway in PDGF-BB induced myocardial fibrosis in rats[J]. Am J Transl Res, 2014, 6(6): 714-723
[17] Tada H, Ogushi F, Tani, et al. Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis[J]. Radiat Res, 2003, 159(6): 805-811. DOI: 10.1667/0033-7587(2003)159[0805:ibacco]2.0.co;2
[18] Hill RP, Zaidi A, Mahmood J, et al. Investigations into the role of inflammation in normal tissue response to irradiation[J]. Radiother Oncol, 2011, 101(1): 73-79. DOI: 10.1016/j.radonc.2011.le06.017
[19] Tofield A. ACE inhibitor reduces radiation injury to myocardium[J]. Eur Heart J, 2013, 34(27): 2023-2024
[20] Paun A, Kunwar A, Haston CK. Acute adaptive immune response correlates with late radiation-induced pulmonary fibrosis in mice[J]. Radiat Oncol, 2015, 10: 45. DOI: 10.1186/s13014-015-0359-y
[21] Judge JL, Lacy SH, Ku WY, et al. The lactate dehydrogenase inhibitor gossypol inhibits radiation-induced pulmonary fibrosis[J]. Radiat Res, 2017, 188(1): 35-43. DOI: 10.1667/RR14620.1
[22] Bledsoe TJ, Nath SK, Decker RH. Radiation Pneumonitis[J]. Clin Chest Med, 2017, 38(2): 201. DOI: 10.1016/j.ccm.2016.12.004
[23] 夏露露, 陈伟, 高民, 等. 放射性肺损伤及康复研究进展[J]. 临床与病理杂志,2019,39(6):1342-1348. DOI: 10.3978/j.issn.2095-6959.2019.06.032
Xia LL, Chen W, Gao M, et al. Research progress in radiation-induced lung injury and rehabilitation[J]. J Clin Pathol Res, 2019, 39(6): 1342-1348. DOI: 10.3978/j.issn.2095-6959.2019.06.032
[24] George PM, Wells AU. Pirfenidone for the treatment of idiopathic pulmonary fibrosis[J]. Expert Rev Clin Pharmacol, 2017, 10: 483-491. DOI: 10.1080/17512433.2017.1295846
[25] Lee JG, Shim S, Kim MJ, et al. Pentoxifylline regulates plasminogen activator inhibitor-1 expression and protein kinase A phosphorylation in radiation-induced lung fibrosis[J]. Biomed Res Int, 2017, 2017: 1279280. DOI: 10.1155/2017/1279280
[26] Anscher MS, Thrasher B, Zgonjanin L, et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury[J]. Int J Radiat Oncol Biol Phys, 2008, 71(3): 829-837. DOI: 10.1016/lej.ijrobp.2008.02.046
[27] Flechsig P, Dadrich M, Bickelhaupt S, et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals[J]. Clin Cancer Res, 2012, 18(13): 3616-3627. DOI: 10.1158/1078-0432.CCR-11-2855
[28] Dadrich M, Nicolay NH, Flechsig P, et al. Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis[J]. Oncoimmunology, 2016, 5(5): e1123366. DOI: 10.1080/2162402X.2015.1123366
[29] Bickelhaupt S, Erbel C, Timke C, et al. Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis[J]. J Natl Cancer Inst, 2017, 109(8). DOI: 10.1093/jnci/djw339
[30] Sternlicht MD, Wirkner U, Bickelhaupt S, et al. Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab[J]. Respir Res, 2018, 19(1): 14. DOI: 10.1186/s12931-018-0720-4
[31] Thomas DM, Fox J, Haston CK. Imatinib therapy reduces radiation-induced pulmonary mast cell influx and delays lung disease in the mouse[J]. Int J Radiat Biol, 2010, 86(6): 436-444. DOI: 10.3109/09553001003674863
[32] Cerri S, Monari M, Guerrieri A, et al. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment[J]. Respir Med, 2019, 159: 105803. DOI: 10.1016/j.rmed.2019.105803
[33] Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic[J]. J Med Chem, 2015, 58(3): 1053-1063. DOI: 10.1021/jm501562a
[34] Varone F, Sgalla G, Iovene B, et al. Nintedanib for the treatment of idiopathic pulmonary fibrosis[J]. Expert Opin Pharmacother, 2018, 19(2): 167-175. DOI: 10.1080/14656566.2018.1425681
[35] Ruan H, Lv Z, Liu SS, et al. Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway[J]. J Pharm Pharmacol, 2020, 72(1): 44-55. DOI: 10.1111/jphp.13183
[36] Ziegler V, Henninger C, Simiantonakis I, et al. Rho inhibition by lovastatin affects apoptosis and DSB repair of primary human lung cells in vitro and lung tissue in vivo following fractionated irradiation[J]. Cell Death Dis, 2017, 8(8): e2978. DOI: 10.1038/cddis.2017.372
[37] Monceau V, Pasinetti N, Schupp C, et al. Modulation of the Rho/ROCK pathway in heart and lung after Thorax irradiation reveals targets to improve normal tissue toxicity[J]. Curr Drug Targets, 2010, 11(11): 1395-1404. DOI: 10.2174/1389450111009011395
[38] Bao PT, Zhao WG, Li Y, et al. Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study[J]. Med Oncol, 2015, 32(1): 405. DOI: 10.1007/s12032-014-0405-x
|
|
|
|
